Expression vector suitable for expression of a coding sequence for gene therapy

a technology of expression vectors and gene therapies, applied in the field of expression vectors for gene therapy, can solve the problems of transient and not sustained expression level of hfix in human subjects

Active Publication Date: 2012-11-08
MOGAM BIOTECH RES INST
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024]Accordingly, it is an object of the present invention to provide a polynucleotide which can be used as a transcriptional regulatory element for sustained expression of a liver tissue-specific gene at a high level.
[0025]It is another object of the present invention to provide an expression vector for sustained expression of a liver tissue-specific gene at a high level.

Problems solved by technology

However, when such highly efficient expression vector for an animal model was clinically applied to a human patient, the blood concentration of FIX was only 185 ng / ml or less, which is less than 500 ng / ml, the threshold value for an effective clinical treatment, and besides, the problem was that the hFIX expression level in a human subject was not sustained but transient (Kay, M. A., Nat. Genet., 24: 257-261 (2000); Manno, C. S., Nat. Med., 12: 342-347 (2006)).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Expression vector suitable for expression of a coding sequence for gene therapy
  • Expression vector suitable for expression of a coding sequence for gene therapy
  • Expression vector suitable for expression of a coding sequence for gene therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation and Activity Analysis of Liver Tissue-Specific Expression Promoters and Enhancers

Isolation and Activity Analysis of Liver Tissue-Specific Expression Promoters

[0108]Genomic DNA was extracted from a cell lysate of human liver cell line (Chang cells) by using a DNeasy Tissue Kit (Qiagen). In order to isolate a FVII promoter, PCR was performed using the genomic DNA as a template, a primer set of SEQ ID NOS: 1 and 2, and DNA polymerase (Ex-Taq, Takara) to obtain a DNA fragment having the nucleotide sequence of SEQ ID NO: 41. Specifically, PCR was carried out under the following conditions: initial denaturation at 94° C. for five minutes; 30 cycles of denaturation at 94° C. for 30 seconds, annealing at 56° C. for 30 seconds and extension at 72° C. for one minute; and final extension at 72° C. for three minutes. The PCR products were purified by gel extraction and inserted into a pCR2.1-TOPO plasmid vector. The FVII promoter having the nucleotide sequence of SEQ ID NO: 41 was id...

example 2

Isolation of UTRs of hFIX and Introns of Liver-Specific Genes, and Analysis of Gene Expression Efficiency by UTRs and Introns

[0128] Identification of UTRs of hFIX, and Construction of Expression Vectors Including UTRs

[0129]1.2 mg of total RNA was extracted from 1 g of a human liver tissue, which was previously homogenized with a homogenizer, using a RNA extraction kit (Pharmacia Biotech). A single-stranded DNA was synthesized using the extracted RNA as a template, an M-MuLV reverse transcriptase (Takara) and oligo-dT17 primers (Takara), and a double-stranded cDNA was synthesized from the single-stranded DNA using DNA polymerase I (Takara).

[0130]In order to evaluate the effect of FIX UTR on gene expression efficiency, PCR was performed using the cDNA as a template, a primer set (SEQ ID NOS: 11 and 12) designed from a nucleotide sequence of FIX (Genbank accession No: NM000133) and Ex-Taq to obtain FIX cDNA including 5′UTR (SEQ ID NO: 62) and 3′UTR (SEQ ID NO: 63). The PCR condition wa...

example 3

Isolation of Liver-Specific LCRs and Analysis of Gene Expression Efficiency by LCRs

Isolation of Liver-Specific LCRs and Construction of Plasmid Vectors Including LCRs

[0160]The positions of the TGTTTGC motif was analyzed in the downstream of α1-antitrypsin, α-fetoprotein and albumin genes expressed only in the liver tissues. The results are shown in FIG. 10.

[0161]As shown in FIG. 10, seven TGTTTGC motifs are distributed at −7.8 kb site of α1-antitrypsin gene, six motifs being in a forward orientation and one motif being in a reverse orientation, and one motif is located in a forward orientation at −108 bp site of α1-antitrypsin gene. At −3.8 kb site of α-fetoprotein, two TGTTTGC motifs are distributed in a forward orientation and one motif is in a reverse orientation and at −6 kb site of albumin gene, one motif is located in a reverse orientation. In addition, TGTTTGC motifs are clustered at −800 bp site of the α1-antitrypsin gene, −1.5 kb and −500 bp sites of the α-fetoprotein gene...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Divisional application of U.S. patent application Ser. No. 12 / 867,716 filed Aug. 13, 2010, which is a National Stage of International Application No. PCT / KR2008 / 000870 filed Feb. 14, 2008, the contents of all of which are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to an expression vector for gene therapy, and more particularly, to an expression vector for gene therapy including a novel combination of transcriptional regulatory elements (cis-regulatory elements or cis-acting elements) which include a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR), said vector being capable of sustaining the expression of a target gene at a high level in the liver.BACKGROUND OF THE INVENTION[0003]The functions of the liver include blood storage, sugar conversion and the secretion of various cytokines, as well as the expres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N15/63C12N15/113C12N15/11C12N15/67C12N15/85
CPCC12N15/63C12N15/11
Inventor KOH, DAEKYUNGLEE, KYUHYUNLEE, HYEONYUN, SEONGTAEJO, EUI-CHEOL
Owner MOGAM BIOTECH RES INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap